Why not work at depleting the problematic protein that causes a disease condition? This is the approach taken by Kymera and I think even if we have once and done Gene therapy cures, Kymera will still have a market because the once and done therapies are very expensive and many that cannot afford the once and done therapy or those who would like to wait longer will surely go for protein depletion therapies to manage their condition. Please check out this video as I take a closer look at Kymera Therapeutics in our initial video. Many more to follow as they have an interesting pipeline.


Please subscribe: [ Ссылка ]

00:00:00 Introduction
00:33:17 Title track
00:38:14 Explaining the approach and contrasting with gene therapy
02:14:29 Clip from Kymera explaining Protein depletion approach
04:52:05 Clip from Kymera explaining the Pegasus platform
06:32:17 Looking at pipeline with focus on KT474
08:22:23 Technical analysis on price chart
10:39:17 Conclusions


The videos in this channel should not be construed as financial advice. Always make sure to do your own due diligence and research.
Please do not trade or Invest based on this video. Information provided in this video is not investment advice and is for entertainment purposes only.

свернуть